Recent clinical trials observed satisfactory survival results of PD-1/PD-L1 inhibitors in melanoma, non-small-cell lung cancer (NSCLC), head and neck cancer, and cutaneous squamous cell carcinoma (39–42). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.